These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17998477)

  • 1. Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury.
    Deeb RS; Upmacis RK; Lamon BD; Gross SS; Hajjar DP
    Hypertension; 2008 Jan; 51(1):1-7. PubMed ID: 17998477
    [No Abstract]   [Full Text] [Related]  

  • 2. Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.
    Capra V; Bäck M; Barbieri SS; Camera M; Tremoli E; Rovati GE
    Med Res Rev; 2013 Mar; 33(2):364-438. PubMed ID: 22434418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selective inhibitors of cyclooxygenase-2: new perspectives of human diseases management].
    Nasonov EL; Tsvetkova ES; Tov NL
    Ter Arkh; 1998; 70(5):8-14. PubMed ID: 9644734
    [No Abstract]   [Full Text] [Related]  

  • 4. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
    FitzGerald GA
    Nat Rev Drug Discov; 2003 Nov; 2(11):879-90. PubMed ID: 14668809
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostaglandins and inflammation.
    Ricciotti E; FitzGerald GA
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):986-1000. PubMed ID: 21508345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 inhibitors in the treatment of cardiovascular disease.
    Peterson JC
    CMAJ; 2002 Oct; 167(7):738-9; author reply 739-40. PubMed ID: 12389824
    [No Abstract]   [Full Text] [Related]  

  • 7. COX-2 inhibitors in the treatment of cardiovascular disease.
    Raynauld JP
    CMAJ; 2002 Oct; 167(7):739; author reply 739-40. PubMed ID: 12389825
    [No Abstract]   [Full Text] [Related]  

  • 8. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
    Widlansky ME; Price DT; Gokce N; Eberhardt RT; Duffy SJ; Holbrook M; Maxwell C; Palmisano J; Keaney JF; Morrow JD; Vita JA
    Hypertension; 2003 Sep; 42(3):310-5. PubMed ID: 12874094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
    Monsuez JJ
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 inhibitors--is there cause for concern?
    Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
    Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy.
    Onn A; Tseng JE; Herbst RS
    Clin Cancer Res; 2001 Nov; 7(11):3311-3. PubMed ID: 11705841
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cardiovascular risks of selective COX-2-inhibitors].
    Schrör K
    Dtsch Med Wochenschr; 2004 Dec; 129(49):2653-6. PubMed ID: 15578320
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical pharmacology of selective inhibitors of cyclooxygenase-2].
    Patrignani P
    Acta Otorhinolaryngol Ital; 2003 Aug; 23(4 Suppl 74):13-8, 37-40. PubMed ID: 15058604
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of rheumatoid arthritis--we're getting closer.
    Kushner I; Ballou SP
    J Rheumatol; 1999 Nov; 26(11):2291-3. PubMed ID: 10555878
    [No Abstract]   [Full Text] [Related]  

  • 16. Bases for a spinal analgesic action of cyclooxygenase inhibitors.
    Vanegas H
    Proc West Pharmacol Soc; 2002; 45():225-7. PubMed ID: 12434585
    [No Abstract]   [Full Text] [Related]  

  • 17. COX in a crystal ball: current status and future promise of prostaglandin research.
    FitzGerald GA; Loll P
    J Clin Invest; 2001 Jun; 107(11):1335-7. PubMed ID: 11390412
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
    Baigent C; Patrono C
    Arthritis Rheum; 2003 Jan; 48(1):12-20. PubMed ID: 12528099
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicine. Estrogen's ties to COX-2 may explain heart disease gender gap.
    Couzin J
    Science; 2004 Nov; 306(5700):1277. PubMed ID: 15550635
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
    Hedner T; Himmelmann A
    Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.